Drugs / LBL-007
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04640545 | May 2020 → Aug 2024 | metastatic melanoma | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07099430 | Sep 2025 → Oct 2027 expected | melanoma | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05102006 | Nov 2021 → May 2024 | cancer | Nanjing Leads Biolabs Co.,Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06010303 | Nov 2023 → May 2025 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05909904 | Aug 2023 → Jun 2025 | head and neck squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05635708 | Mar 2023 → Dec 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-03-06 | BeOne Medicines | Results BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024 beonemedicines.com ↗
An additional preclinical presentation highlights the therapeutic potential of the triple-combination of tislelizumab with anti-LAG-3 (LBL-007) and anti-TIM-3 (surzebiclimab); this combination is being evaluated in an ongoing Phase 2 study in head and neck squamous cell carcinoma (NCT05909904). |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBL-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04164199 ↗ |
| Route | Intravenous | “administered intravenously” NCT04640545 ↗ |